Trial · NCT06359782
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
NCT06359782, Phase 2, Recruiting, Haaglanden Medical Centre
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH). Trials, record NCT06359782. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06359782
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
- NCT number
- NCT06359782
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Haaglanden Medical Centre
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- C1 Esterase Inhibitor Injection [Cinryze], Placebo
- First posted
- 2024-04-11
- Last updated
- 2024-12-27
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with delayed cerebral ischemia (DCI) | To be determined between day 4 and day 14 of admission | Defined as either a new focal neurological impairment, or a decrease of at least 2 points on the Glasgow Coma Scale. This should last for at least 1 hour, is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or MRI scanning of the brain, and appropriate laboratory studies. |
| Primary | Number of participants with complications during hospitalization. | Up to 1 year after admission | Complication rate during hospitalization |
| Secondary | Number of participants with cerebral infarction on brain CT | at 14 days after admission | |
| Secondary | Number of participants dying | Up to 1 year after admission | Mortality rate |
| Secondary | Neurological condition measured by Glasgow Coma Scale | During the first 14 days | Measured daily, minimum value of 3, maximal value of 15, higher scores mean a better outcome |
| Secondary | Complement activity markers measured in serum and CSF | Before IV administration of C1-INH or placebo, and after 48 hours and 96 hours after IV administration | WIESLAB, C3b/C, C4b/C, C5b-9 ELISA assays, CH50/AC50 |
| Secondary | Inflammatory markers measured in serum and CSF | Before IV administration of C1-INH or placebo, and after 48 hours and 96 hours after IV administration | TNF-alpha, intraleukins |
| Secondary | Number of days in the hospital | Up to 1 year | Hospital length of stay |
| Secondary | Number of ICU days | Up to 1 year | ICU length of stay |
| Secondary | Number of ventilator days | Up to 1 year | Ventilator days |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06359782
GET https://conductscience.org/api/trials/v1/NCT06359782/registered